Zydus gets final USFDA approval for their tablets containing hydrochlorothiazide and bisoprolol fumarate

The US Food and Drug Administration (USFDA) has granted final approval to Zydus Lifesciences to market Bisoprolol Fumarate and Hydrochlorothiazide tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg (USRLD: Ziac tablets).

High blood pressure should be treated with a combination of bisoprolol fumarate and hydrochlorothiazide (hypertension).
The group’s formulation manufacturing facility in Ahmedabad SEZ, India, will produce the medication.

Shopping Cart
Scroll to Top